ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Biogen has licensed MT-1303, a small-molecule autoimmune drug in Phase II clinical trials, from Japan’s Mitsubishi Tanabe Pharma, for $60 million up front and up to $484 million in milestone payments. Like the Novartis multiple sclerosis (MS) treatment Gilenya, which was licensed from Mitsubishi Tanabe, MT-1303 targets the sphingosine 1-phosphate receptor. Biogen is assessing its potential in MS, ulcerative colitis, Crohn’s disease, and other autoimmune ailments.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter